Middle East Journal of Rehabilitation and Health

Published by: Kowsar

Probiotics and Inflammatory Pain: A Literature Review Study

Vida Nazemian 1 , 2 , Mahdi Shadnoush 2 , 3 , Homa Manaheji 1 , 4 and Jalal Zaringhalam 1 , 4 , *
Authors Information
1 Neurophysiology Research Centre, Shahid Beheshti University of Medical Sciences, Tehran,IR Iran
2 Faculty of Medicine, Semnan University of Medical Sciences, Semnan, IR Iran
3 Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Department of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Middle East Journal of Rehabilitation and Health: April 01, 2016, 3 (2); e36087
  • Published Online: March 1, 2016
  • Article Type: Review Article
  • Received: January 8, 2016
  • Revised: February 15, 2016
  • Accepted: February 15, 2016
  • DOI: 10.17795/mejrh-36087

To Cite: Nazemian V, Shadnoush M, Manaheji H, Zaringhalam J. Probiotics and Inflammatory Pain: A Literature Review Study, Middle East J Rehabil Health Stud. 2016 ; 3(2):e36087. doi: 10.17795/mejrh-36087.

Copyright © 2016, Semnan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N. Immune system stimulation by probiotics. J Dairy Sci. 1995; 78(7): 1597-606[DOI][PubMed]
  • 2. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009; 15(2): 300-10[DOI][PubMed]
  • 3. McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil. 2010; 22(9): 1029-35[DOI][PubMed]
  • 4. Reid G. Probiotics and prebiotics – Progress and challenges. Int Dairy J. 2008; 18(10-11): 969-75[DOI]
  • 5. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol. 2010; 16(33): 4145-51[PubMed]
  • 6. Pineda Mde L, Thompson SF, Summers K, de Leon F, Pope J, Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit. 2011; 17(6)-54[PubMed]
  • 7. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008; 46 Suppl 2-100[DOI][PubMed]
  • 8. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014; 30(4): 430-5[DOI][PubMed]
  • 9. Lilly DM, Stillwell RH. Probiotics: Growth-Promoting Factors Produced by Microorganisms. Science. 1965; 147(3659): 747-8[PubMed]
  • 10. Parker RB. Probiotics, the other half of the antibiotic story. Anim Nutr Health. 1974; 29(29): 4-8
  • 11. Stanton C, Gardiner G, Meehan H, Collins K, Fitzgerald G, Lynch PB, et al. Market potential for probiotics. Am J Clin Nutr. 2001; 73(2 Suppl): 476S-83S[PubMed]
  • 12. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr. 1998; 80 Suppl 1-71[PubMed]
  • 13. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol. 1998; 39(3): 237-8[PubMed]
  • 14. Asano M, Karasawa E, Takayama T. Antitumor activity of Lactobacillus casei (LC 9018) against experimental mouse bladder tumor (MBT-2). J Urol. 1986; 136(3): 719-21[PubMed]
  • 15. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006; 100(6): 1171-85[DOI][PubMed]
  • 16. Kato I, Endo K, Yokokura T. Effects of oral administration of Lactobacillus casei on antitumor responses induced by tumor resection in mice. Int J Immunopharmacol. 1994; 16(1): 29-36[PubMed]
  • 17. Lee JW, Shin JG, Kim EH, Kang HE, Yim IB, Kim JY, et al. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. J Vet Sci. 2004; 5(1): 41-8[PubMed]
  • 18. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010; 10: 1[DOI][PubMed]
  • 19. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006; 83(6): 1256-64[PubMed]
  • 20. Araya M, Morelli L, Reid G, Sanders ME, Stanton C. Joint fao/who working group report on guidelines for the evaluation of probiotics in food London, Ontario 2002;
  • 21. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc. 2001; 101(2): 229-38[DOI][PubMed]
  • 22. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011; 3(6): 637-82[DOI][PubMed]
  • 23. Shadnoush M, Hosseini RS, Khalilnezhad A, Navai L, Goudarzi H, Vaezjalali M. Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial. Korean J Gastroenterol. 2015; 65(4): 215-21[DOI][PubMed]
  • 24. Isolauri E. Probiotics in human disease. Am J Clin Nutr. 2001; 73(6): 1142S-6S[PubMed]
  • 25. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003; 361(9356): 512-9[DOI][PubMed]
  • 26. Lahtinen S, Ouwehand AC, Salminen S, von Wright A. Lactic acid bacteria: microbiological and functional aspects. 2011;
  • 27. Kleeman EG, Klaenhammer TR. Adherence of Lactobacillus species to human fetal intestinal cells. J Dairy Sci. 1982; 65(11): 2063-9[DOI][PubMed]
  • 28. Fuller R. Probiotics in human medicine. Gut. 1991; 32(4): 439-42[PubMed]
  • 29. Wilson KH, Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun. 1988; 56(10): 2610-4[PubMed]
  • 30. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999; 67(1): 302-7[PubMed]
  • 31. Rastall RA. Bacteria in the gut: friends and foes and how to alter the balance. J Nutr. 2004; 134(8 Suppl): 2022S-6S[PubMed]
  • 32. Yeganehzad S, Mazaheri-Tehrani M, Shahidi F. Studying microbial, physiochemical and sensory properties of directly concentrated probiotic yoghurt. Africa J Agr Res. 2007; 2(8): 366-9
  • 33. Lescheid DW. Probiotics as regulators of inflammation: A review. Func Food Health Dis. 2014; 4(7): 299-311
  • 34. De Simone C, Ciardi A, Grassi A, Lambert Gardini S, Tzantzoglou S, Trinchieri V, et al. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol Immunotoxicol. 1992; 14(1-2): 331-40[DOI][PubMed]
  • 35. Famularo G, Moretti S, Marcellini S, De Simone C. Stimulation of immunity by probiotics. 1997; : 133-61
  • 36. Schiffrin EJ, Brassart D, Servin AL, Rochat F, Donnet-Hughes A. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr. 1997; 66(2): 515S-20S[PubMed]
  • 37. De Simone C, Vesely R, Bianchi Salvadori B, Jirillo E. The role of probiotics in modulation of the immune system in man and in animals. Int j immunotherapy. 1993; 9(1): 23-8
  • 38. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun. 1996; 64(12): 5403-5[PubMed]
  • 39. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol. 2000; 95(1 Suppl)-21[PubMed]
  • 40. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003; 36(2): 223-7[PubMed]
  • 41. Zubillaga M, Weill R, Postaire E, Goldman C, Caro R, Boccio J. Effect of probiotics and functional foods and their use in different diseases. Nutr Res. 2001; 21(3): 569-79[DOI]
  • 42. Pelto L, Isolauri E, Lilius EM, Nuutila J, Salminen S. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin Exp Allergy. 1998; 28(12): 1474-9[PubMed]
  • 43. Mersky H, Bodguk N. Task force on taxonomy of the international association for the study of pain: Classification of chronic pain, description of chronic pain syndromes and definition of pain terms. 1994;
  • 44. Basbaum A, Bushnell MC, Devor M. Pain: basic mechanisms. Pain. 2002; : 3-7
  • 45. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60(11): 1524-34[DOI][PubMed]
  • 46. Gilroy DW. The endogenous control of acute inflammation – from onset to resolution. Drug Discov Today. 2004; 1(3): 313-9[DOI]
  • 47. Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001; 87(1): 3-11[PubMed]
  • 48. Rodriguez-Vita J, Lawrence T. The resolution of inflammation and cancer. Cytokine Growth Factor Rev. 2010; 21(1): 61-5[DOI][PubMed]
  • 49. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov. 2004; 3(5): 401-16[DOI][PubMed]
  • 50. Zaringhalam J, Akhtari Z, Eidi A, Ruhani AH, Tekieh E. Relationship between serum IL10 level and p38MAPK enzyme activity on behavioral and cellular aspects of variation of hyperalgesia during different stages of arthritis in rats. Inflammopharmacology. 2014; 22(1): 37-44[DOI][PubMed]
  • 51. Zaringhalam J, Akbari A, Tekieh E, Manaheji H, Rezazadeh S. Achillea santolina reduces serum interlukin-6 level and hyperalgesia during complete Freund's adjuvant-induced inflammation in male Wistar rats. J China Integ Med. 2010; 8(12): 1180-9[DOI]
  • 52. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001; 70(6): 849-60[PubMed]
  • 53. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000; 52(4): 595-638[PubMed]
  • 54. Min YD, Choi CH, Bark H, Son HY, Park HH, Lee S, et al. Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res. 2007; 56(5): 210-5[DOI][PubMed]
  • 55. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996; 14: 397-440[DOI][PubMed]
  • 56. Tawfik VL, Regan MR, Haenggeli C, Lacroix-Fralish ML, Nutile-McMenemy N, Perez N, et al. Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transection. Neuroscience. 2008; 152(4): 1086-92[DOI][PubMed]
  • 57. van den Berg WB, Joosten LA, van de Loo FA. TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheumatol. 1999; 17(6 Suppl 18)-14[PubMed]
  • 58. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003; 17(16): 1969-78[DOI][PubMed]
  • 59. Zaringhalam J, Tekieh E, Manaheji H, Akhtari Z. Cellular events during arthritis-induced hyperalgesia are mediated by interleukin-6 and p38 MAPK and their effects on the expression of spinal mu-opioid receptors. Rheumatol Int. 2013; 33(9): 2291-9[DOI][PubMed]
  • 60. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996; 63(1): 116-22[PubMed]
  • 61. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50(5): 1400-11[DOI][PubMed]
  • 62. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 1999; 5(10): 439-47[PubMed]
  • 63. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 1995; 27(5): 537-41[DOI][PubMed]
  • 64. Zaringhalam J, Hormozi A, Tekieh E, Razavi J, Khanmohammad R, Golabi S. Serum IL-10 involved in morphine tolerance development during adjuvant-induced arthritis. J Physiol Biochem. 2014; 70(2): 497-507[DOI][PubMed]
  • 65. Akthari Z, Eidi A, Manaheji H, Tekieh E, Zaringhalam J. Bidirectional effects of serum TNF alpha level and spinal P38MAPK phosphorylation on hyperalgesia variation during CFA-induced arthritis. EXCLI J. 2012; 11: 373-85
  • 66. Alani B, Maghsoudi N, Manaheji H, Tekieh E, Zardooz H, Zaringhalam J. Increased serum IL-6 level time-dependently regulates hyperalgesia and spinal mu opioid receptor expression during CFA-induced arthritis. EXCLI J. 2011; 10: 23-33
  • 67. Shadnoush M, Shaker Hosseini R, Mehrabi Y, Delpisheh A, Alipoor E, Faghfoori Z, et al. Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. Iran J Pharm Res. 2013; 12(4): 929-36[PubMed]
  • 68. Zaringhalam J, Manaheji H, Mghsoodi N, Farokhi B, Mirzaiee V. Spinal mu-opioid receptor expression and hyperalgesia with dexamethasone in chronic adjuvant-induced arthritis in rats. Clin Exp Pharmacol Physiol. 2008; 35(11): 1309-15[DOI][PubMed]
  • 69. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer seminars in immunopathology.
  • 70. Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut. 2006; 55(6): 815-23[DOI][PubMed]
  • 71. Goldsmith JR, Uronis JM, Jobin C. Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling. Am J Pathol. 2011; 179(2): 673-83[DOI][PubMed]
  • 72. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004; 16(4): 383-94[DOI][PubMed]
  • 73. Antonijevic I, Mousa SA, Schafer M, Stein C. Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci. 1995; 15(1 Pt 1): 165-72[PubMed]
  • 74. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 1995; 332(25): 1685-90[DOI][PubMed]
  • 75. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007; 13(1): 35-7[DOI][PubMed]
  • 76. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59(3): 325-32[DOI][PubMed]
  • 77. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A. 2008; 105(43): 16767-72[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments